The pituitary gland has been found to be an important factor in mammary development in primates. Hypophysectomy in 12 sexually immature monkeys caused significant inhibition of estradiol (E2)-induced mammary growth and development. A histological index of mammary development in sexually immature hypophysectomized animals was lower (0.82) than in intact E2-treated controls (3.4; P less than 0.008). Hypophysectomy also inhibited growth of the mammary gland as judged by a size index. Despite the hypophysectomy, E2 stimulated some, albeit blunted, mammary growth and development, which may have been due to incomplete hypophysectomy. Selective inhibition of prolactin by ergot drugs in intact animals did not prevent full mammary development, suggesting that there may be pituitary mammogens other than prolactin, or that very low or unmeasurable concentrations of prolactin were sufficient to synergize with E2 to cause full acinar development. The mean histological index was 3.08 in E2-treated animals and 3.16 in animals treated with E2 plus pergolide. There was also no difference in the size of the glands. We evaluated the effect of growth hormone on mammary development by treating three hypophysectomized animals with pure 22,000 mol wt human growth hormone (hGH) (Genentech, Inc., South San Francisco, CA). We found that physiological or slightly supraphysiological concentrations of hGH in animals with unmeasurable prolactin were incapable of restoring the capacity of E2 to induce […] Our studies suggest that the role of the pituitary gland in mammary mitogenesis in primates is more complicated than previously thought. They also raise the possibility that heretofore unidentified pituitary substances may be mammogenic.
Introduction
In recent years the medical community has focused attention away from the pituitary gland as a potential source Received for publication 18 September 1984 and in revised form 6 February 1985. may have been that prolactin-lowering ergots have not been effective in the treatment of metastatic breast cancer in humans (1) , as they are in rats with dimethylbenzanthracene-induced tumors (2) , and another is that tamoxifen therapy has virtually replaced hypophysectomy in treating metastatic breast cancer. Several convincing lines of evidence, however, indicate that the pituitary gland does play a role in the growth and maintenance of breast cancer in humans (3) (4) (5) (6) (7) (8) (9) . Doubts about the relationship of the pituitary to human breast cancer have raised questions about the relationship of the pituitary gland to normal mammary mitogenesis in primates, a subject which has not been addressed. Previous well-designed studies in lower mammals have led many to assume that the process of mammary development in primates is a relatively uncomplicated one in which prolactin and growth hormone synergize with estrogen and other hormones to induce full mammary development (10) (11) (12) (13) (14) (15) (16) (17) (18) .
In retrospect, however, those studies, in which prolactin and growth hormone were found to be important mammogens were potentially flawed because they employed huge concentrations of relatively impure hormones to make their determinations. Not only might one hormone have been contaminated with enough of the other to provide physiological concentrations of the contaminant, but the pituitary extract might have contained other unidentified hormones of potential importance. In our view, a reevaluation of the individual and combined effects of prolactin and growth hormone in mammary development and the importance of the pituitary gland itself in mammary development in primates was essential before accepting the premise that mammary development was as uncomplicated as it was once thought to be and that studies in rodents were applicable to humans.
We chose the subhuman primate to study the importance of the pituitary gland in mammary growth and the role of physiological concentrations of prolactin and growth hormone in estradiol (E2)'-induced mammary development for three reasons: (a) to mimic the human situation as closely as possible and to determine whether there were species differences between rodents and primates, (b) to utilize an animal model in which serum concentrations of hormones could be regularly measured in individual samples and during 24-h periods, and (c) to utilize a species in which growth hormone was highly lactogenic.
Our initial findings are presented in this paper.
Methods
Studies were carried out in 23 sexually immature monkeys (17 males and 6 females) weighing 2-2.5 kg (Macaca nemestrina or Macaca mulatta), in 4 sexually mature and regularly cycling adult female monkeys (M. mulatta), and in 6 sexually immature male dogface baboons. Animals were housed singly in cages and fed monkey chow, oranges, apples, and water ad lib. Blood samples were drawn weekly under ketamine tranquilization. In addition to these weekly bloods, some animals had 24- (24), which utilizes a-lactalbumin production as the endpoint. Pergolide mesylate (kindly supplied by Eli Lilly Laboratories, Indianapolis, IN), a long-acting dopamine agonist which has a duration of action of greater than 24 h (25), was used to inhibit prolactin in animals with intact pituitaries. It was given in doses from 200 to 500 gg daily by injection. After it became apparent that it was not always possible to do a complete hypophysectomy and that low but detectable concentrations of prolactin were found in some animals, we treated all remaining hypophysectomized animals with 500 1Ag of pergolide daily to insure that prolactin would be as completely inhibited as possible. We did not find that chronic treatment with pergolide raised growth hormone in either intact or hypophysectomized animals.
Prolactin and growth hormone were measured by previously described radioimmunoassays (26, 27). The sensitivity of both assays for serum samples was 1 ng/ml. Values of <1 ng/ml were assumed to be 0 in calculating means. Statistical analyses were done using the Wilcoxon two-sample rank sum test. Two-tailed paired t test was also used to determine correlation coefficients.
Results

Effect of E2
Treatment of sexually immature subhuman primates (M. nemestrina and M. mulatta) with E2 led to full mammary development resembling that of adult female animals within a 2-mo period (Table I) . Two were females and three were males. Both prolactin and growth hormone were higher during E2 treatment than before. Mean serum prolactin before E2 treatment was 3.96 ng/ml in these five control animals. During E2 therapy, the mean serum prolactin during 2 mo was increased to a mean of 10.6 ng/ml. Mean growth hormone for the entire group was 4.81 ng/ml before any treatment and 15.75 ng/ml during E2 therapy.
During treatment the mammary glands matured both in size and in histological development ( Figs. 1 and 2 ). Gland size increased in four of the five animals. There was a mean increase of 272.6% of control. Histological examination revealed that initially the immature mammary glands were composed Effect of hypophysectomy on E2-induced mammary development
Hypophysectomy was found to inhibit E2-induced mammary development in all 12 animals studied (Table II) . The completeness of hypophysectomy was judged by stimulation of prolactin by TRH and of growth hormone by insulin-induced hypoglycemia. These tests were done before and after hypophysectomy. Peak responses of prolactin and growth hormone to TRH and insulin, respectively, before and after hypophysectomy in individual animals are shown in Fig. 3 . The postoperative peaks were blunted in all cases. Mean reduction in peak growth hormone responses to hypoglycemia was 77.3% (range, 36-98%) and mean reduction in peak prolactin responses to TRH was 95.4% (range, 67-100%). Concentrations of serum prolactin and growth hormone were also measured before the hypophysectomy and weekly during the 2-mo course of E2 treatment. Before hypophysectomy, mean serum prolactin was 4.87 ng/ml and growth hormone was 3.51 ng/ml. Mean weekly prolactin and growth hormone concentrations during the experimental period are listed individually in Table II . Mean prolactin and growth hormone values for the entire group during therapy (assuming 0 for values of <1) was 0.89 and 0.85 ng/ml, respectively, representing reductions of 82 and 76%. The significance of these reductions in prolactin and growth hormone due to hypophysectomy is even greater when one considers the fact that E2 would have led to a greater than 2.5-fold increase in growth hormone and prolactin had the animals been intact (vide supra). After it became obvious that a total hypophysectomy was not always possible, we began to treat animals with a dopamine agonist, pergolide, to prevent increases in prolactin. These animals are identified in Table II. Hypophysectomy prevented full E2-induced mammary development. The mean histological grade in the E2-treated, hypophysectomized animals (0.82) was significantly lower than in intact animals treated with estradiol alone (3.4; P < 0.008). That full E2-induced mammary development was not entirely inhibited by hypophysectomy was evidenced by a significant increase in histological development (control 0.083 vs. treated 0.82; P < 0.0003) in hypophysectomized animals treated with E2. Whether more complete hypophysectomy would have prevented the mammary development observed has not been ascertained. There was, however, a significant correlation between the concentration of serum growth hormone during the experiment and the histological score (R = +0.704; P < 0.02), but the correlation between prolactin concentrations and histological development was not significant. The mean size index of 112.75% of base line was also significantly lower than that observed with E2 treatment in intact animals (P < 0.015), suggesting that total mammary size was inhibited by hypophysectomy.
Effect ofselective inhibition ofprolactin on
E2induced mammary development (Table III) . After 6 wk, a 24-h sampling of prolactin was carried out in all the animals. Mean prolactin in the three animals receiving both drugs was 1.74 ng/ml (range, 0.58-2.8 ng/ml); control animals receiving E2 without pergolide had a mean 24-h prolactin concentration of 11 ng/ ml (range, 2.9-15.5 ng/ml). Before any treatment, the mean 24-h prolactin in the three untreated animals which later received pergolide was 5.8 ng/ml (range, 4.3-8.2 ng/ml). Thus, in the 24-h studies, prolactin in animals receiving E2 and pergolide when compared with untreated controls was reduced by a mean of 72%. Prolactin inhibition was 85% or more in random weekly bloods. Treatment with E2 caused an increase in serum growth hormone in all animals whether or not they received pergolide (Table IV) . The mean of six individual 24-h studies for growth hormone before taking E2 was 5.7±1.6 ng/ml. It was 16.8±3 ng/ml in the six E2-treated animals. Pergolide had no significant stimulatory or inhibitory effect on serum growth hormone.
Mean 24-h growth hormone was 14.1 ng/ml in the three animals treated with pergolide and E2, and 19.4 ng/ml in the animals receiving E2 alone.
Examination of the mammary glands before and after treatment revealed that full mammary development was not inhibited by selective inhibition of prolactin using both the mean histological grade and the size index (Table III) .
Dogface baboons. Similar experiments were carried out in a group of six sexually immature male dogface baboons. Unfortunately, full histological data were available in only four (one E2-treated control and three animals treated with E2 and pergolide). Prolactin was significantly inhibited in all four animals receiving pergolide both in 24-h studies during treat- animal was given 100 ,ug of Genentech 22,000 mol wt hGH at 9 a.m. and 200 1Ag at 5-6 p.m. (Fig. 5) . The other two received 50 usg in the morning and 100 jsg in the evening. Mean 24-h hGH was 14.8 ng/ml in the animal receiving the higher dose and 10.1 ng/ml in one of the animals receiving the lower dose. In the other, a 24-h study was not done because the animal expired suddenly 1 wk before the end of the experiment. Therefore, in that animal, only random morning specimens before the daily injection of growth hormone were available for testing. As in the other animals, a unilateral mastectomy was (lone at the time of insertion of the E2 capsule, at which time the growth hormone was also started. After 2 mo (7 wk in one animal), the other gland was removed. There was some mammary development in each of three animals during the 2-mo test period (Table VI) . In no case, however, was the mean histological grade > 2.0. In each case there was proliferation of intraductal epithelial cells, suggesting heightened stimulation of the gland but no acinar development was evident.
Discussion
Our results provide evidence that the pituitary gland plays a vital role in mammary development in subhuman primates. When the pituitary glands of 12 sexually immature monkeys were removed, E2-induced mammary development was significantly blunted. Thus it appears that primates resemble lower mammals (10) (11) (12) (13) (14) (15) (16) (17) (18) (28) (29) (30) . On the other hand, if prolactin is mammogenic, the function of the pituitary gland in mammary mitogenesis must be more complicated than previously thought. It is possible that minute concentrations of prolactin are sufficient to synergize with estrogens to induce mammary growth or that there are other forms of prolactin not recognized by presently utilized antisera to prolactin. Other substances of pituitary 
